New for 2017. Providing broad and diverse exposure to biotechnology companies
International Biotechnology is managed by a three-strong team at SV Life Sciences - Carl Harald Janson, Kate Bingham and Ailsa Craig, whose backgrounds combine medical and/or scientific training, financial and commercial experience.
This experience enables them to assess potential investment opportunities from a position of technical expertise and experience, and consider which companies are the most likely to succeed.
The trust invests in unquoted, usually earlier stage companies, as well as quoted equities. This broad spectrum of investments provides diversification while still giving exposure to potentially exciting returns.
The managers invest in companies whose shares they consider to have good prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
They specialise in identifying the successful innovative drugs and medical devices that will serve unmet medical needs in complex disease areas such as diabetes and cancer, as well as the most credible treatments for 'orphan' diseases where the number of patients may be fewer but the path to approval may be smoother with less competition.
The type of companies select provides investors with exposure to businesses at different stages of their development, from early stage innovation, across regulatory hurdles, through to regulatory approval and revenue generation.
The main aim of the trust is to provide long-term capital growth, but in 2016 a dividend equivalent to 4 per cent of net asset value was introduced, which is expected to be paid out of capital reserves.